by In2Pharma | Jul 1, 2020 | News
Belgium On June 30, the transfers of value from the pharmaceutical and medical device industry to the healthcare industry have been disclosed on betransparent.be. This is already the third disclosure of collaborations under the legal framework of the Sunshine Act. A...
by In2Pharma | Jun 30, 2020 | News
Belgium On June 19th 2020, the law implementing the saving measures for the healthcare budget 2020, has been published. This implies that the saving measures will come into force as of July 1st 2020. Please find herewith the link to the law in NL and FR. Source:...
by In2Pharma | Jun 11, 2020 | News
Europe Marketing authorisation holders (MAHs) are asked to take precautionary measures to mitigate the risk of nitrosamine formation or presence during the manufacture of all medicines containing chemically synthesised active substances. The MAHs were obliged to...
by In2Pharma | Jun 11, 2020 | News
The Netherlands For safety reasons, the Medicines Evaluation Board portal was provisionally taken offline in January this year and unfortunately the MEB made the decision to close down the portal permanently. Due to the closure of the portal, the following services...
by In2Pharma | Jun 11, 2020 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy on Direct Healthcare Professional Communications (DHPCs) for medicinal products for human use. The update includes the following: “The marketing authorisation holder must attach one (or more)...
by In2Pharma | Jun 11, 2020 | News
Belgium According to the financing law of FAMHP, a declaration of the number of packages of medicines sold on the Belgian market must be submitted annually to define the yearly contributions. Up to now, every marketing authorization holder and wholesaler of medicines...
